1. United States of America Stocks

  2. •

    Healthcare

  3. •

    Biotechnology
10x Genomics, Inc.

10x Genomics, Inc.

TXG
10x Genomics, Inc.US flagNASDAQ Global Select
84.11
USD
+8.49
- -
10.68BMarket Cap

Total Valuation

10x Genomics, Inc. carries a market capitalization of 10.68B, placing it among publicly traded companies globally. Its enterprise value stands at 4.52B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Market Cap10.68B
Enterprise Value4.52B

Share Statistics

10x Genomics, Inc. currently has 130.28M shares outstanding.

Shares Outstanding130.28M
Owned by Insiders (%)N/A
Owned by Institutions (%)N/A

Valuation Ratios

The price-to-sales ratio is 7.94, and the price-to-book ratio stands at 6.05.

PE RatioN/A
PS Ratio7.94
PB Ratio6.05
P/TBV Ratio6.59
P/FCF Ratio36.89
P/OCF Ratio38.53

Enterprise Valuation

EV / Sales7.33
EV / EBITDAN/A
EV / EBITN/A
EV / FCF34.07

Financial Position

10x Genomics, Inc. maintains a current ratio of 5.69, meaning it holds 5.7x the short-term assets needed to cover near-term liabilities.

Current Ratio5.69
Quick Ratio5.09
Debt / Equity9.54
Debt / EBITDA-1.80
Interest CoverageN/A

Financial Efficiency

Return on Equity (ROE)-9.40
Return on Assets (ROA)-7.47
Return on Invested Capital (ROIC)N/A
Return on Capital Employed (ROCE)N/A
Revenue Per EmployeeN/A
Employee CountN/A
Inventory Turnover3.04

Taxes

Income Tax235,000.00
Effective Tax RateN/A

Stock Price Statistics

10x Genomics, Inc.'s stock has gained approximately 597.42952% over the past 52 weeks. The 50-day moving average sits at 59.54, while the 200-day moving average is 32.57.

Beta (5Y)N/A
52-Week Price Change597.42952%
50-Day Moving Average59.54
200-Day Moving Average32.57
Average Volume (20 Days)N/A

Income Statement

Over the trailing twelve months, 10x Genomics, Inc. generated 616.91M in revenue and converted that into -75.12M in net income, yielding earnings per share of -0.59. EBITDA reached -43.84M, while operating income came in at -91.78M.

Revenue616.91M
Gross Profit432.03M
Operating Income-91.78M
Pretax Income-74.89M
Net Income-75.12M
EBITDA-43.84M
EBIT-91.78M
Earnings Per Share (EPS)-0.59

Balance Sheet

10x Genomics, Inc. holds 552.03M in cash and equivalents against 78.80M in total debt, resulting in a net debt position of -502.51M. Total book value stands at 825.55M, with working capital of 556.16M providing operational flexibility.

Cash & Cash Equivalents552.03M
Total Debt78.80M
Net Debt-502.51M
Equity (Book Value)825.55M
Book Value Per Share6.34
Working Capital556.16M

Cash Flow

10x Genomics, Inc. produced 127.09M in operating cash flow over the past twelve months. After subtracting -5.65M in capital expenditures, free cash flow totaled 121.44M - equivalent to 0.95 per share.

Operating Cash Flow127.09M
Capital Expenditures-5.65M
Free Cash Flow121.44M
FCF Per Share0.95

Margins

10x Genomics, Inc. operates with a gross margin of 70.03, reflecting its pricing power and cost economics. The operating margin of -14.88 and net profit margin of -12.18 provide insight into operational efficiency.

Gross Margin70.03
Operating Margin-14.88
Pretax Margin-12.14
Profit Margin-12.18
EBITDA Margin-7.11

Dividends & Yields

Dividend Per ShareN/A
Dividend YieldN/A
Payout RatioN/A
Shareholder Yield0.05
FCF Yield2.71

Stock Splits

10x Genomics, Inc.'s most recent stock split took place on July 17, 2006 with a 2:1 split ratio.

Last Split Date7/17/2006
Split Ratio2:1

Scores

10x Genomics, Inc. posts an Altman Z-Score of 13.43, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.

Altman Z-Score13.43